Category: News

Precision Medicine - Biomarkers & Diagnostics

The Montpellier Cancer Institute du Cancer and Acobiom announce the signature of a partnership agreement for a clinical trial in pancreatic cancer

The partnership between the Institut du Cancer Montpellier (ICM) and Acobiom is to confirm the predictive value of two patented RNA signatures

The Intricate Interplay between Innate Immunity and Pancreatic Cancer

Innate immunity’s role in pancreatic cancer is complex. It impacts inflammation, immune surveillance, and the tumor microenvironment, influencing disease progression and potential treatments.

A new diagnostic to predict the patient response to FOLFIRINOX in pancreatic cancer

Innovation in pancreatic cancer: Acobiom develops the 1st blood-based diagnostic to identify the patients most likely to benefit from FOLFIRINOX as 1st-line treatment.

GemciTest classification OS-PFS

Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC, representing more than 90% of pancreatic cancer cases is a highly lethal cancer, and chemotherapy is a key treatment for advanced PDAC. Gemcitabine chemotherapy is still an important component of treatment. Although, according to several clinical trials (Conroy, T. et al. N Engl J Med. 2011; Von Hoff, D. et al.…
Read more

Eurobio Scientific and Acobiom announce the signature of an exclusive commercial agreement for the distribution of a diagnostic test that predicts response to a treatment for pancreatic cancer

Eurobio Scientific and Acobiom announce the signature of an exclusive commercial agreement for the distribution of a diagnostic test that predicts response to a treatment for pancreatic cancer

• CE marked test for patients with pancreatic ductal adenocarcinoma
• Prediction of response to first-line gemcitabine-based chemotherapy
• Developed and validated with real world data and samples

GemciTest - In vitro diagnostic medical device for the prediction of patient response in the treatment of the pancreas with gemcitabine

Dr. Noelle LoConte (MD, University of Wisconsin) presents the predictive performance of GemciTest®

Pancreatic cancer is a highly lethal cancer. For several years, gemcitabine has been one of the main chemotherapies used to treat this cancer. But there is no routine biomarker to predict its efficacy.
Dr. Noelle LoConte presented the results of using GemciTest® in a confirmatory study, which shows the predictive performance of this in-vitro diagnostic based on PCR technology and a blood RNA signature.

ACOBIOM obtains the hi-France label from AFPC

ACOBIOM obtains the hi-France label from AFPC

The French Association of Competitiveness Poles (FACP) awards ACOBIOM the hi-France label, the label of innovative companies to invest in.

Acobiom uses real world data (RWD).

Real-World Data as the basis for predictive diagnostics developed by ACOBIOM

Based on Real-World Data and Real-World Evidence, ACOBIOM contributes to better therapeutic decisions and thus allows to give the right treatment to the right patient.

ACOBIOM propose un nouveau service: mesurer l’inflammation dans les organes et le sang par Digital PCR ou PCR en Temps-Réel

ACOBIOM provides a new service: measuring inflammation in organs and blood by Digital or Real-Time PCR

Based on its proprietary database of gene expression profiles and its scientific expertise, ACOBIOM selected a panel of genes to measure inflammation in organs and blood. This Digital or Real-Time PCR assay allows the company to extend its range of services.

Real Time qPCR plaque

Target genes and specific reference genes, a unique marriage for successful RT-PCR experiments

Gene expression analyses by real-time PCR (or qPCR) are currently used to measure drug effects or to identify subpopulations of patients mostly likely to benefit from a specific therapy. The success of a qPCR experiment relies on the combination of a unique triptych: the selection of relevant and regulated target genes, the identification of a couple or more stable and experiment-specific reference genes, also called housekeeping genes, and robust statistical analyses. Thus, if some consider the target genes as the Kings of their experiment, the reference genes are the Queens of the equation!